Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment.

Abstract:

INTRODUCTION:Our objectives were to design and validate methods to identify relapse and hematopoietic stem cell transplantation (HSCT) in children with acute lymphoblastic leukemia (ALL) using administrative data representing hospitalizations at US pediatric institutions. METHODS:We developed daily billing and ICD-9 code definitions to identify relapses and HSCTs within a cohort of children with newly diagnosed ALL between January 1, 2004, and December 31, 2013, previously assembled from the Pediatric Health Information System (PHIS) database. Chart review for children with ALL at the Children's Hospital of Philadelphia (CHOP) and Texas Children's Hospital (TCH) was performed to establish relapse and HSCT gold standards for sensitivity and positive predictive value (PPV) calculations. We estimated incidences of relapse and HSCT in the PHIS ALL cohort. RESULTS:We identified 362 CHOP and 314 TCH ALL patients in PHIS and established true positives by chart review. Sensitivity and PPV for identifying both relapse and HSCT in PHIS were > 90% at both hospitals. Five-year relapse incidence in the 10 150-patient PHIS cohort was 10.3% (95% CI 9.8%-10.9%) with 7.1% (6.6%-7.6%) of children underwent HSCTs. Patients in higher-risk demographic groups had higher relapse and HSCT rates. Our analysis also identified differences in incidences of relapse and HSCT by race, ethnicity, and insurance status. CONCLUSIONS:Administrative data can be used to identify relapse and HSCT accurately in children with ALL whether they occur on- or off-therapy, in contrast with published approaches. This method has wide potential applicability for estimating these incidences in pediatric ALL, including patients not enrolled on clinical trials.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Cahen VC,Li Y,Getz KD,Elgarten CW,DiNofia AM,Wilkes JJ,Winestone LE,Huang YV,Miller TP,Gramatges MM,Rabin KR,Fisher BT,Aplenc R,Seif AE

doi

10.1002/pbc.28315

subject

Has Abstract

pub_date

2020-05-11 00:00:00

pages

e28315

eissn

1545-5009

issn

1545-5017

pub_type

杂志文章
  • Minor anomalies in children with hematological malignancies.

    abstract:BACKGROUND:Despite the presence of reports on correlation between major congenital defects and cancer, very few studies have investigated the frequency of minor anomalies in childhood malignancy. The aim of this study was to determine the prevalence of minor anomalies in children with hematological malignancy. PROCEDU...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22689

    authors: Citak FE,Citak EC,Akkaya E,Kosan B,Ezer U,Kurekci AE

    更新日期:2011-02-01 00:00:00

  • Recurrent melanotic neuroectodermal tumor in the orbit successfully treated with resection followed by pediculated periosteal flaps.

    abstract::Melanotic neuroectodermal tumor of infancy (MNTI) is a rare tumor arising mainly in the orofacial bones. Among more than 200 cases described in articles, only seven cases involved orbital regions. We present a case of newborn with recurrent MNTI in the lateral wall of right orbit. The patient underwent complete surgic...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21607

    authors: Nakanishi K,Hori H,Matsubara T,Matsuda K,Deguchi T,Komada Y

    更新日期:2008-09-01 00:00:00

  • Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years.

    abstract:BACKGROUND:In the pediatric population, pathologic bleeding is often challenging to identify. The pediatric bleeding questionnaire (PBQ) was developed as a screening tool for von Willebrand disease (VWD) but was designed to be self-completed by children above 12 years of age. The study objective was to determine whethe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27709

    authors: Bui J,Martyres D,James PD,Grabell J,Wu J,Steele M,Silva M,Rand ML,Blanchette VS,Barrowman N,Klaassen RJ

    更新日期:2019-06-01 00:00:00

  • Protein biomarkers for incident deep venous thrombosis in critically ill adolescents: An exploratory study.

    abstract:BACKGROUND:There are no tests to identify critically ill children at high risk of deep venous thrombosis (DVT). In this exploratory study, we aimed to identify proteins that are associated with incident DVT in critically ill adolescents. PROCEDURE:Plasma samples were obtained from critically ill adolescents within 24 ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.28159

    authors: Tala JA,Polikoff LA,Pinto MG,Li S,Trakas E,Miksa M,Gertz S,Faustino EVS,THEIA Study Investigators.

    更新日期:2020-04-01 00:00:00

  • Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease.

    abstract:BACKGROUND:Pulmonary hypertension (PHTN) is a potentially life-threatening complication, detected by echocardiographic evidence of elevated tricuspid regurgitant velocity (TRV). This condition has been described in adults with sickle cell disease (SCD) and other hemolytic disorders; however, there is little information...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20791

    authors: Ambrusko SJ,Gunawardena S,Sakara A,Windsor B,Lanford L,Michelson P,Krishnamurti L

    更新日期:2006-12-01 00:00:00

  • Efficacy and toxicity of plerixafor for peripheral blood stem cell mobilization in children with high-risk neuroblastoma.

    abstract::Six patients with high-risk neuroblastoma underwent the second stem cell collection round with G-CSF (5 μg/kg/day) + plerixafor (0.24 mg/kg/day) because the amount of CD34(+) cells collected during the first collection round with G-CSF alone was insufficient. The number of CD34(+) cells collected in the second collect...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24506

    authors: Son MH,Kang ES,Kim DH,Lee SH,Yoo KH,Sung KW,Koo HH,Kim DW,Kim JY,Cho EJ

    更新日期:2013-08-01 00:00:00

  • Cyclophosphamide disposition in an anephric child.

    abstract::Although limited data are available about cyclophosphamide disposition in patients with renal insufficiency, nothing has been reported in anephric patients. We characterized cyclophosphamide pharmacokinetics in an anephric child with bilateral Wilms tumor, both on (day 1) and off (day 2) hemodialysis. The median cyclo...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20558

    authors: McCune JS,Adams D,Homans AC,Guillot A,Iacono L,Stewart CF

    更新日期:2006-01-01 00:00:00

  • A single-center experience with undifferentiated embryonal sarcoma of the liver.

    abstract::Undifferentiated embryonal sarcoma of the liver (UESL) is a rare aggressive mesenchymal pediatric tumor. Previously, reported outcomes have been very poor. Here, we report a single-center experience of five patients with UESL treated with upfront gross total resection and adjuvant chemotherapy. We have a median follow...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26154

    authors: Mathias MD,Ambati SR,Chou AJ,Slotkin EK,Wexler LH,Meyers PA,Magnan H

    更新日期:2016-12-01 00:00:00

  • Psychological resilience in adolescent and young adult survivors of lower extremity bone tumors.

    abstract:BACKGROUND:The psychosocial outcomes of young adult survivors of childhood bone tumors are not well known. This study: (a) examined perceived social support (SS) and benefit-finding (BF) with respect to surgical intervention, gender, and age; (b) compared SS and psychological outcomes to normative values; and (c) exami...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24441

    authors: Teall T,Barrera M,Barr R,Silva M,Greenberg M

    更新日期:2013-07-01 00:00:00

  • Parental informed consent in pediatric cancer trials: a population-based survey in Germany.

    abstract:BACKGROUND:Ensuring adequate parental consent is a key issue of ethical practice in pediatric oncology. In Germany, however, knowledge about parental comprehension and satisfaction with the informed consent procedure is limited, and representative data on parents' perspectives are still missing. Based on data collected...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24330

    authors: Petersen I,Spix C,Kaatsch P,Graf N,Janka G,Kollek R

    更新日期:2013-03-01 00:00:00

  • Familial small cell carcinoma of the ovary.

    abstract::Ovarian tumors have a low incidence in childhood, accounting for 1% of malignancies within the ages of 0-17 years. Small cell carcinoma of the ovary is a rare histology and historically has a poor prognosis. We report a case of an 11-year-old female diagnosed with small cell carcinoma of the ovary and hypercalcemia (S...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22184

    authors: Martinez-Borges AR,Petty JK,Hurt G,Stribling JT,Press JZ,Castellino SM

    更新日期:2009-12-15 00:00:00

  • Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.

    abstract::Anaplastic oligodendroglioma (AO) is rare in children. Treatment typically consists of varying combinations of surgery, chemotherapy, and radiotherapy. We present a pediatric case of frontal lobe AO with periventricular subcallosal extension and local leptomeningeal involvement. The isocitrate dehydrogenase (IDH) wild...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.26708

    authors: Sorge C,Li R,Singh S,Reddy AT,Solomon DA,Perry A,Friedman GK

    更新日期:2017-12-01 00:00:00

  • Implementation of an educational intervention to optimize self-management and transition readiness in young adults with sickle cell disease.

    abstract:BACKGROUND:The transition from the pediatric setting to adult care is a well-described period of morbidity and mortality for persons with sickle cell disease (SCD). We sought to measure the feasibility and effectiveness of providing skill-based educational handouts on improving self-management and transition readiness ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27722

    authors: Calhoun CL,Abel RA,Pham HA,Thompson S,King AA

    更新日期:2019-07-01 00:00:00

  • The association between timely opioid administration and hospitalization in children with sickle cell disease presenting to the emergency department in acute pain.

    abstract:INTRODUCTION:The National Heart, Lung, and Blood Institute guidelines for sickle cell disease (SCD) pain crisis management recommend opioids within 60 minutes of emergency department (ED) registration and every 30 minutes thereafter until acute pain is managed. These guidelines are based on expert opinion without publi...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28268

    authors: Muslu CS,Kopetsky M,Nimmer M,Visotcky A,Fraser R,Brousseau DC

    更新日期:2020-09-01 00:00:00

  • Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.

    abstract:BACKGROUND:We assessed the safety and efficacy of ifosfamide and vinorelbine (IV) as a less toxic and effective reinduction regimen for pediatric patients with relapsed or refractory Hodgkin Lymphoma. PROCEDURE:This multi-center Children's Oncology Group phase II pilot study enrolled patients <30 years of age with bio...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.25205

    authors: Trippett TM,Schwartz CL,Guillerman RP,Gamis AS,Gardner S,Hogan S,London WB,Chen L,de Alarcon P

    更新日期:2015-01-01 00:00:00

  • No improvement in clinical trial enrollment for adolescents and young adults with cancer at a children's hospital.

    abstract:BACKGROUND:We have previously published data from 2001 to 2006 showing that adolescent and young adult (AYA) oncology patients have significantly lower therapeutic clinical trial enrollment rates than younger patients. Our objective was to determine if the enrollment of AYA patients on therapeutic studies at the same i...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26638

    authors: Jacob SA,Shaw PH

    更新日期:2017-12-01 00:00:00

  • Cancer incidence and survival trends among infants in the United States from 1975 to 2014.

    abstract:BACKGROUND:Cancer among infants (<1 year old) has unique epidemiologic, clinical, and genetic characteristics compared with cancer in older children. Nonetheless, data on secular trends in infant cancer incidence and survival in the United States is sparse. METHODS:Population-based data from nine areas of the Surveill...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28917

    authors: Wang H,Mejia MC,Gonzalez SJ,Zoorob RJ,Chai W,Du XL

    更新日期:2021-01-20 00:00:00

  • Promoting adherence in adolescents and young adults with cancer to optimize outcomes: A developmentally oriented narrative review.

    abstract::Adherence is a critical consideration in ongoing efforts to improve outcomes among adolescents and young adults (AYAs) with cancer. In this narrative review, we embed existing conceptualizations of adherence within a developmental context to provide a novel vantage point from which to examine this important issue. App...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.28128

    authors: Vandermorris A,Sampson L,Korenblum C

    更新日期:2020-04-01 00:00:00

  • Palliative radiotherapy for pediatric patients: Parental perceptions of indication, intent, and outcomes.

    abstract:OBJECTIVES:Palliative radiation therapy (pRT) is often used to improve quality of life for pediatric patients. Though palliative doses are generally lower than those for cure, pRT may still introduce undesirable effects. The decision to pursue additional therapy for a child may be challenging and depends on parents' kn...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28003

    authors: Lee BK,Boyle PJ,Zaslowe-Dude C,Wolfe J,Marcus KJ

    更新日期:2020-01-01 00:00:00

  • APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.

    abstract:BACKGROUND:MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) are effective therapies for Hodgkin disease (HD) that may cause long-term toxicities in children. APE (cytosine arabinoside, cisplatin, etoposide) is a non-cross-resistant regimen wit...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20563

    authors: Wimmer RS,Chauvenet AR,London WB,Villaluna D,de Alarcon PA,Schwartz CL

    更新日期:2006-03-01 00:00:00

  • Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies.

    abstract::Essential thrombocythemia is a rare myleoproliferative disorder in pediatrics. This myleoproliferative disorder is characterized by excessive proliferation of megakaryocytes and sustained elevation of platelet count. Reactive thrombocytosis is a more common cause of elevated platelet counts among children. We describe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21218

    authors: Robins EB,Niazi M

    更新日期:2008-04-01 00:00:00

  • Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.

    abstract:BACKGROUND:Adolescents with acute lymphoblastic leukaemia (ALL) have languished in the shadow of success of the outcome of therapy in childhood ALL. Their treatment has always been incorporated into either paediatric or adult clinical trials depending on the mode of referral and hence there is a need to address an age ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20749

    authors: Ramanujachar R,Richards S,Hann I,Goldstone A,Mitchell C,Vora A,Rowe J,Webb D

    更新日期:2007-03-01 00:00:00

  • Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.

    abstract:BACKGROUND:The level of minimal residual disease (MRD) prior to allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an independent prognostic factor for outcome of pediatric patients with high-risk acute lymphoblastic leukemia (ALL). Retrospective studies which used (semi-) quantitation of cl...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.20794

    authors: Sramkova L,Muzikova K,Fronkova E,Krejci O,Sedlacek P,Formankova R,Mejstrikova E,Stary J,Trka J

    更新日期:2007-01-01 00:00:00

  • Outcome after first relapse in children with acute lymphoblastic leukemia: a report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol.

    abstract:BACKGROUND:We report on the treatment of children and adolescents with acute lymphoblastic leukemia (ALL) in first relapse. The protocol focused on: (1) Intensive chemotherapy preceding allogeneic stem cell transplantation (SCT) in early bone marrow relapse; (2) Rotational chemotherapy in late relapse, without donor; (...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.22946

    authors: van den Berg H,de Groot-Kruseman HA,Damen-Korbijn CM,de Bont ES,Schouten-van Meeteren AY,Hoogerbrugge PM

    更新日期:2011-08-01 00:00:00

  • Deficiencies in the Management of Iron Deficiency Anemia During Childhood.

    abstract::Limited high-quality evidence supports the management of iron deficiency anemia (IDA). To assess our institutional performance in this area, we retrospectively reviewed IDA treatment practices in 195 consecutive children referred to our center from 2006 to mid-2010. The majority of children were ≤4 years old (64%) and...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25861

    authors: Powers JM,Daniel CL,McCavit TL,Buchanan GR

    更新日期:2016-04-01 00:00:00

  • Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.

    abstract:BACKGROUND:The combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mammalian target of rapamycin (mTOR) has shown activity in preclinical models of pediatric sarcoma and in adult sarcoma patients. We evaluated the activity of the anti-IGF-1R antibody cixutumumab with the mTOR inhibitor temsiro...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.25334

    authors: Wagner LM,Fouladi M,Ahmed A,Krailo MD,Weigel B,DuBois SG,Doyle LA,Chen H,Blaney SM

    更新日期:2015-03-01 00:00:00

  • Treatment of intestinal and hepatic mucormycosis in an immunocompromized child.

    abstract::During ALL chemotherapy, a 4-year-old patient presented with febrile neutropenia and abdominal pain. Ultrasound examinations were repeatedly normal. Computerized tomography on day 7 demonstrated appendicitis and multiple hepatic foci identified as mucormycosis (Absidia corymbifera). Successful outcome was achieved by ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21918

    authors: Lüer S,Berger S,Diepold M,Duppenthaler A,von Gunten M,Mühlethaler K,Wolf R,Aebi C

    更新日期:2009-07-01 00:00:00

  • Eating behaviors and dietary quality in childhood acute lymphoblastic leukemia survivors.

    abstract:BACKGROUND:Childhood acute lymphoblastic leukemia (ALL) survivors' increased risk for adverse health outcomes could be mitigated through consuming a balanced diet. Nonetheless, >70% of adult survivors do not meet survivorship dietary recommendations. ALL treatment may amplify risk for restricted dietary preferences (pi...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28811

    authors: Chardon ML,Pinto S,Slayton WB,Fisher RS,Janicke DM

    更新日期:2020-12-31 00:00:00

  • Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation.

    abstract::Pneumocystis jiroveci pneumonia (PCP) is a serious complication in patients receiving chemotherapy or hematopoietic stem cell transplantation. Current recommendations for trimethoprim-sulfamethoxazole (TMP-SMZ) dosing as PCP prophylaxis in immunocompromised patients are based on either daily dosing or dosing three con...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21774

    authors: Ohata Y,Ohta H,Hashii Y,Tokimasa S,Ozono K,Hara J

    更新日期:2009-01-01 00:00:00

  • A novel mutation of ABCG5 gene in a Turkish boy with phytosterolemia presenting with macrotrombocytopenia and stomatocytosis.

    abstract::Phytosterolemia is a rare autosomal recessive sterol storage disease caused by mutations in ABCG5 and ABCG8 genes. A 9-year-old Turkish boy who was presented with exclusively hematologic abnormalities had elevated plant sterol levels. Sequencing of ABCG5 and ABCG8 genes revealed a novel homozygous IVS10-1 G>T mutation...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24934

    authors: Kaya Z,Niu DM,Yorulmaz A,Tekin A,Gürsel T

    更新日期:2014-08-01 00:00:00